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The aim of the present study was to investigate the association between polymorphism
in  the interleukin-10 gene promoter at position −1082 in human immunodeﬁciency virus-
infected patients who had presented allergic reaction due to efavirenz. The study included
63  patients treated at the Hospital São José de Doenc¸as Infecciosas, Fortaleza, Ceará, Brazil.
Twenty-one patients who had presented allergic reaction to efavirenz were compared to
42  patients with no allergic reaction following exposure to this drug. Blood samples were
collected for DNA extraction and submitted to the restriction fragment length polymor-
phism – polymerase chain reaction technique. The −1082AA genotype was signiﬁcantly
more frequent in allergic patients as compared to non-allergic patients (p = 0.019; 2 = 5.534;
OR  = 3.625; 95% CI = 1.210–10.860). Likewise the allele IL-10 −1082A was identiﬁed signiﬁ-
cantly more often among efavirenz allergic patients than in the non-allergic group (p = 0.009;
2 = 6.787; OR = 3.029; 95% CI = 1.290–7.111). These ﬁndings suggest that the polymorphismin  the interleukin-10 gene promoter −1082G/A can be related to the development of allergic
reactions to efavirenz.
© 2014 Elsevier Editora Ltda. All rights reserved.∗ Corresponding author.
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According to the World Health Organization (WHO), the
term adverse drug reaction (ADR) can be deﬁned as any
noxious or unintended reaction that appears after drug
administration at standard doses, for the purpose of pro-
phylaxis, diagnosis and treatment of a disease.1 Clinical
manifestations of adverse reactions to antiretroviral drugs can
affect individuals on various levels of severity. The most com-
mon  ADRs occur early in therapy and include gastrointestinal
effects, such as nausea, bloating, and diarrhea, which may
be transient or persistent. Less common reactions include
Zidovudine AZT-associated anemia and hypersensitivity to
non-nucleoside reverse transcriptase inhibitors (NNRTIs).2
It is known that viral infections, such as those caused by
Epstein–Barr virus (EBV) and human immunodeﬁciency virus
(HIV), constitute increased risk factors for the development of
drug hypersensitivity. In the case of HIV, studies have shown
that the frequency of drug hypersensitivity is estimated to be
in the range of 3–20%, and that skin rashes related to drugs
are 100 times more  frequent in HIV-infected patients than
in the general population.3 The main adverse effects asso-
ciated with efavirenz, a drug which belongs to the NNRTI
class, are due to disorders of the central nervous system
(CNS), such as dizziness, drowsiness, headache, inability to
concentrate, nightmares, and depression. These effects can
be observed in approximately 40% of patients in the early
days or weeks of treatment.4 In addition to these effects, it
is reported that drug rashes occur in 27% of the adults and
45% of the children, occurring around the second week of
treatment.5 The increased frequency of drug allergy in HIV
patients can be attributed to immune system dysregulation
or vulnerability to oxidative stress. Drug exposure is a neces-
sary component, but not the only causative agent that induces
drug allergy. Allergy also depends on individual susceptibility.
In this way, individual susceptibility is thought to be multi-
factorial, including genetic factors.3,5 Some studies of genetic
predisposition to antiretroviral allergy have shown a strong
association between the presence of HLA-B* 5701 and hyper-
sensitivity to abacavir.6,7 Thus, screening for this allele before
the initiation of antiretroviral therapy could be important
in the identiﬁcation of patients at increased risk for allergic
reaction to abacavir.8 Other genetic studies have shown that
polymorphism of genes that regulate cytokine production can
affect the individual immune response.9
Interleukin-10 (IL-10) is an important anti-inﬂammatory
cytokine secreted by various cells of the immune system,
including T lymphocytes, macrophages, dendritic cells and
monocytes. This cytokine has immunoregulatory effects such
as inhibition of pro-inﬂammatory cytokines IL-1, IL-6, IL-12,
IL-18 and tumor necrosis factor TNF, as well as co-stimulatory
molecules on antigen-presenting cells.10 Single nucleotide
polymorphisms (SNP) at positions −1082 (A/G), −819 (T/C),
−592 (C/A) of the proximal promoter region of the IL-10 gene
may affect the cytokine in vitro production.11,12 The pres-
ence of the A allele at position −1082 seems to be associated
with low levels of IL-10 production, and occurs indepen-
dently of polymorphisms at other positions.11 The aim of the
present study is to investigate the association between aller-
gic reaction to efavirenz and polymorphism in the promoter
region of the IL-10 gene at position −1082G > A in HIV-infected
patients. 1 4;1  8(4):445–448
This is a case control study involving 63 HIV-infected adult
patients on Highly Active Antiretroviral Therapy (HAART)
receiving care at Hospital São José Infectious Diseases in
Fortaleza, Ceará, Brazil. Case deﬁnition of drug allergy to
efavirenz included rash, skin eruption, urticaria, and/or ery-
thema following exposure to efavirenz. Additionally, efavirenz
withdrawal led to a complete remission of the allergic reaction.
The assistant physicians of patients suspect of having
an allergic reaction to efavirenz were to complete a drug
change/modiﬁcation request form (ADR reporting inform) in
order to discontinue efavirenz and switch to another regimen.
From 2006 to 2012, there were 84 patients with drug reaction
reporting forms who were contacted over telephone calls and
invited to participate in the study. Of those, only 21 eligible
patients were located and agreed with blood collection. There
were nine males and 12 females, aged 24–71 years. The control
group consisted of 32 males and 10 females, aged 20–67 years,
HIV-infected patients on HAART-containing efavirenz for at
least six months without any evidence of adverse cutaneous
reactions to the drug. All the participants signed a written
informed consent. The project was approved by the Ethics
Committee in Research, Hospital São José de Doenc¸as Infec-
ciosas, number 025/2011.
Venipuncture of 4 mL  of whole blood was collected in a tube
containing ethylenediaminetetraacetic acid EDTA  as an anti-
coagulant. DNA was extracted using a commercial extraction
kit, Biopur Extraction Kit Mini Plus Spin – 250 (Biopur, Brazil),
according to the manufacturer’s instructions. Polymorphism
of IL-10 (−1082G > A) was detected by PCR-RFLP, as previously
described by Koch et al.13 The reaction was performed in a
total volume of 20 L reaction solution, using TopTaq Master
Mix (Qiagen, Germany) with addition of 0.01% bovine serum
albumin (BSA), primer at concentration of 20 pmol/L  and
approximately 25 ng of DNA template. The polymerase chain
reaction (PCR) was performed in a thermocycler (Eppendorf,
Germany) under the following conditions: initial denaturation
at 94 ◦C for 4 min, followed by 35 cycles of 94 ◦C for 40 s, 56 ◦C
for 35 s and 72 ◦C for 40 s. The ﬁnal extension was done at
72 ◦C for 5 min. The PCR products of 377 bp were then digested
with restriction endonuclease XagI (Fermentas, Lithuania) at
37 ◦C for 16 h. The 280 and 97 bp fragments corresponded to the
−1082A allele and 253, 97 and 27 bp to the −1082G allele. The
analysis of the digestion products was done by electrophoresis
on 6% polyacrylamide gel after silver staining (Fig. 1).
The statistical analyses were performed using the com-
mercial software GraphPad Prism version 5.00 for Windows,
(GraphPad Prism, Inc., La Jolla, CA, USA). The Chi-square test
was used to test for the association between efavirenz allergy
and genotypic and allelic frequencies. Odds ratio (OR) with a
95% conﬁdence interval was calculated. A p-value < 0.05 was
considered of statistical signiﬁcance.
In the analysis of the allele frequency, a statistically sig-
niﬁcant difference was found comparing case and control
groups (p = 0.009, Table 1). A higher frequency of the A allele
was found in the efavirenz-allergic group. The genotype AA
at the position −1082 for IL-10 was much more  frequentgroup (p = 0.019, Table 1). The OR indicated that the proba-
bility that an individual would present an allergic reaction
to the drug was 3.625 times greater when the in case of AA
b r a z j i n f e c t d i s . 2 0 1 4;1 8(4):445–448 447
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Lane M: 100bp marker; Lane A: PCR product 377bp; Lanes 1-4: Samples -1082AA homozygote;
Lanes 5-6: Samples -1082GA heterozygote.
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rFig. 1 – PCR-RFLP for analysis of the poly
enotype. AA genotype was identiﬁed in 62% of efavirenz-
llergic patients. On the other hand, the genotype GG or GA
t the position −1082 for IL-10 was identiﬁed in 69% of non-
llergic patients. According to Turner et al.,11 the carriage of
he AA genotype at position −1082 is one of the factors which
etermines lower levels of IL-10. Our results demonstrated
hat individuals with the presence of the −1082A allele and
he −1082AA genotype are more  prone to suffer allergy to
favirenz.
It is observed that some patients treated with various drugs
ay exhibit variability in therapeutic response to the drug and
ay have susceptibility to some adverse reactions. Pharmaco-
enetics is gaining wide applicability in clinical pharmacology
nce the study of genetic factors may contribute to the effec-
iveness and safety of drug therapy.14,15
Saag et al.7 evaluated the detection of HLA-B*5701 as a
arker for hypersensitivity to abacavir after conﬁrmation of
rug allergy by patch testing in Black and Caucasian patients
iving in the United States. The results of the survey showed
00% sensitivity for HLA-B*5701 as a marker of drug allergy
o abacavir in both groups. Some other studies suggest that
creening for HLA-B*5701 should be performed before start-
ng the abacavir therapy, thereby reducing the risk of allergic
eactions to this drug.8
Several studies associating polymorphism in the pro-
oter of IL-10 and increased pathogenesis in some infectious
iseases have been carried out. Patients with toxoplasmic
etinochoroiditis were more  frequently carriers of the −1082A
llele (AA + GA genotypes) than controls. It was also sug-
ested that the genotype GA was associated with toxoplasma
etinochoroiditis.16 In another study, it was found that the
Table 1 – Genotypic and allelic frequencies of IL-10 −1082G > A 
among controls.
Polymorphism Genotypic frequency (%) 
Genotype Allergic Controls 
AA 13 (61.90%) 13 (30.95%) 
IL-10 (−1082) GA 07 (33.34%) 20 (47.62%) 
GG 01 (4.76%) 09 (21.43%)
Genotypic frequency: 2 = 5.534; odds ratio (OR) = 3.625; 95% conﬁdence int
The p-value for genotype frequency is calculated by IL-10 −1082AA v
CI = 1.290–7.111.phism IL-10 gene promoter (−1082G/A).
polymorphism in the promoter of IL-10 (−1082G > A) was asso-
ciated with the development of cardiomyopathy in individuals
with Chagas disease. Furthermore, this study could demon-
strate that low expression of the cytokine was associated with
worse cardiac function.17
The association of the polymorphism of IL-10 with hyper-
sensitivity reactions to drugs is promising. A study of
polymorphisms in the promoter of IL-10 at the positions −819
and −592 was conducted in the French population. It was
found that atopic women presenting the genotypes CT or TT
at the position −819 and the genotype CA or AA at the position
−592 had higher risk for developing immediate hypersensitiv-
ity reaction to -lactams. This ﬁnding is relevant because the
alleles −819 T and −592 A are associated with lower expres-
sion of IL-10. In regard to type I hypersensitivity, as IL-10 has
an immunomodulatory activity, its reduction enables the Th2
proﬁle, with consequent stimulation of IL-4, IL-9, and IL-13.
These cytokines favor the production of IgE which culminates
with immediate hypersensitivity.18
Qiao et al.19 observed an association between levels of
speciﬁc IgE, cytokines and polymorphisms of IL-4 C/T and IL-
4RQ576R in patients with penicillin allergy. According to the
authors, the allele IL-4R*Q576 was present more  frequently
in allergic patients than in control subjects. Furthermore, it
was demonstrated that the allele IL-4R*Q576 was associated
with the expression of some types of penicillin-speciﬁc IgE,
which included benzylpenicilloyl, phenoxomethylpenicillanyl
and ampicillanyl.The different forms of exanthems (rashes) are the most fre-
quent drug reactions. Some appear rapidly after drug intake,
for example, immediate-type reactions like urticaria and
among patients who  presented allergy to efavirenz and
Allelic frequency
p value Allele Allergic Controls p value
0.019 A 0.79 0.55 0.009
G 0.21 0.45
erval (CI) = 1.210–10.860.
s IL-10 −1082GA/GG. Allelic frequency: 2 = 6.787; OR = 3.029; 95%
i s . 2 0
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angieodema. Others appear hours or days after drug intake;
they are the so-called delayed-type reactions and comprise
a broad spectrum of clinical and distinct histopathological
features.20 In our study, the high frequency of −1082AA geno-
type in the IL-10 gene promoter is probably enabling TCD4
Th1 and/or Th2 proﬁles. Reduction of IL-10 levels promotes
increased activity of CD4+ T lymphocytes of the Th1 and Th2
proﬁles, which would produce a greater quantity of IFN- and
IL-4 respectively.12
Some limitations of our study are related to the high of
refusal rate of patients to join the study. Various factors appear
to be relevant, such as low socioeconomic status, distance
from the patient’s residence to the hospital, inability to under-
stand the purpose of the study, fear of exposing his (her)
disease status to others. We could not perform skin tests to
conﬁrm drug allergy to efavirenz because of logistical reasons
[several readings in the case of epicutaneous tests (24 h, 48 h
and 72 h)].
Our data could suggest that polymorphisms in regulatory
regions of cytokine production are among the factors that may
contribute to an individual susceptibility to drug allergy. Other
studies are necessary to prove our ﬁndings.
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